Hormone Replacement Therapy Market Outlook:
Hormone Replacement Therapy Market size was estimated at over USD 17.9 billion in 2024 and is projected to reach USD 33.5 billion by the end of 2037, exhibiting a CAGR of 5.8% during the forecast period 2025-2037. In 2025, the industry size of the hormone replacement therapy is assessed at USD 18.9 billion.
Key Hormone Replacement Therapy Market Insights Summary:
North America continues to dominate the market, projected to command a 42.8% market share.
The APAC region is anticipated to secure a 17.7% market share with a CAGR of 6.8% by 2037.
Europe is forecasted to account for 29.2% of total revenue, growing steadily at a CAGR of 5.2% by 2037.
The menopause segment is set to maintain its leading position, capturing 43.6% of the market share by 2037.
The estrogen segment is projected to remain the market leader with a 38.4% share by 2037.
Key Growth Trends:
- Increasing government spending
- Rising prevalence of hormone-linked conditions
Key Players:
-
Pfizer Inc., AbbVie Inc., Novo Nordisk A/S, Bayer AG, Merck KGaA, Teva Pharmaceutical Industries, Mylan N.V. (Viatris Inc.), Theramex, Besins Healthcare, Gedeon Richter Plc., Shionogi & Co., Ltd., Aska Pharmaceutical Co., Ltd., Abbott Laboratories, Sun Pharmaceutical Industries, Cipla Ltd., Daewoong Pharmaceutical Co., Samsung Biologics, Mayne Pharma Group Ltd., Duopharma Biotech Berhad, Organon & Co.
-
Market Size and Growth Projections:
- 2024 Market Size: USD 17.9 billion
- 2025 Market Size: USD 18.9 billion
- Projected Market Size: USD 33.5 billion by 2037
- Growth Forecasts: 5.8% CAGR (2025-2037)
- Largest Region: North America
- Fastest Growing Region: Asia Pacific
The market is influenced by rising patient volume among postmenopausal women and individual with endocrine disorders. As per the National Institute on Aging, nearly 1.6 billion women are poised to reach postmenopausal age by 2030, providing sustained combination hormone treatments and demand for estrogen. In the U.S. nearly 6,005 women attain menopause daily with 2.3 million new patients every year. The target base is further expanded by the Centers for Disease Control and Prevention, which notes a rise in age-related thyroid and testosterone deficits at the same time. The production of hormone APIs such as testosterone enanthate, levothyroxine, and estradiol has grown as a result of these patient growth patterns.
On the supply chain side, Germany, the U.S., India, and China actively manufacture active pharmaceutical ingredients (APIs) and export to major pharmaceutical hubs. As per the U.S. Census Bureau’s Foreign Trade Division report, nearly USD 2.6 billion of hormone-based therapeutic products were exported in 2023. Production infrastructure consists of transdermal patch or oral tablet manufacturing lines, medication compounding facilities, and API processing units. These components are frequently divided geographically; formulation and device assembly are primarily done in North America and Western Europe, whereas API manufacture is still primarily done in China and India. The producer price index rose by 3.6% in 2023 for pharmaceutical preparations, while the consumer price index increased by 2.8% for prescription drugs in the same period.
Hormone Replacement Therapy Market - Growth Drivers and Challenges
Growth Drivers
-
Increasing government spending: Government spending on hormone replacement therapy has raised in recent years. In the U.S., Medicare allocated USD 810.6 million to this therapy in 2023, reflecting a 15.6% rise since 2020. This rise is due to expansion in the coverage for postmenopausal women and the aging population. Comparably, in 2023, the Canada federal government has allocated USD 3.7 billion, or 8.7% of its healthcare budget, to health programs for women, going to experience menopause and hormone replacement therapy. Various countries commit to women's aging and endocrine health is demonstrated by this funding.
-
Rising prevalence of hormone-linked conditions: The global incidence of hormone-related disorders is increasing. In Germany, over 6.7 million females received HRT treatment in 2025, a 12.4% increase from 2018. The increase is attributed to late menopause onset and increased awareness of hormone deficiency. Aging women over 51 years and older in the United States are predicted to reach 73.6 million by 2030, increasing demand for HRT to treat menopause, osteoporosis, and endocrine disorders of aging. These projections indicate continued future expansion in the use of HRT.
Historical Patient Growth & Its Impact on Market Dynamics
The rapid increase in the number of afflicted people around the globe from 2010 to 2020 transformed and shaped the current dynamics of demand and consumer base. The rise is due to the shift in demographics, extended life expectancy, increased diagnostic rates, and investments in public health. The historical patient growth continues to rise due to improved drug formulation and revenue opportunities. The patient growth over the past decade forms the foundation of a highly lucrative and competitive market landscape.
Historical Patient Growth (2010-2020) in Key Markets
|
Country |
2010 HRT Patients (Millions) |
2020 HRT Patients (Millions) |
% Growth (2010–2020) |
|
U.S. |
8.9 |
12.6 |
41.2% |
|
Germany |
3.6 |
4.8 |
42.5% |
|
France |
2.8 |
3.4 |
33.7% |
|
Spain |
1.4 |
1.9 |
45.9% |
|
Australia |
1 |
1.5 |
44.8% |
|
Japan |
2.5 |
3.6 |
41.1% |
|
India |
1.8 |
3 |
81.7% |
|
China |
4.1 |
6.7 |
68.8% |
Strategic Expansion Models for Hormone Replacement Therapy Market
Feasible revenue models in the market are transformed by the public-private partnerships, collaborations, and localizations. In the developed countries such as Germany and U.S., the value-based contracts and Medicare reimbursement are used to scale access, ensuring profitability for manufacturers. Whereas in developing countries such as China, the cost-effective and R&D bodies are pushing patient access for past five years. These models reflect the roles of the regional strategies to expand the market.
Feasibility Models for Revenue Growth
|
Country |
Expansion Model |
Revenue Growth (%) |
Key Approach |
|
India |
Regional hospital collaboration + low-cost formulation |
+12.5% |
Public-private partnerships for subsidized generic HRT drug supply |
|
China |
Government-backed co-development + rural access program |
+18.6% (patient access) |
Joint R&D with state health bodies; bulk procurement & rural distribution |
|
U.S. |
Medicare Part D reforms + value-based contracts |
+15.4% |
HRT inclusion in senior care programs; outcome-linked reimbursement models |
|
Germany |
Tiered reimbursement + formulary optimization |
+11.8% |
Multi-level drug pricing policy based on patient severity and age group |
|
Canada |
Provincial subsidy expansion + centralized tendering |
+10.8% |
Expansion of public formularies to cover full HRT regimens |
|
Japan |
Domestic biosimilar production + menopause subsidies |
+10.1% |
Local manufacturing with national subsidy schemes for aging female population |
|
Australia |
National PBS listing for HRT drugs |
+8.9% |
Inclusion in Pharmaceutical Benefits Scheme for wider insurance reimbursement |
Challenges
- Government-imposed price caps: Europe and Asia governments place tight price caps on hormone replacement therapy (HRT) medications to curb national healthcare expenditure, sharply cutting into manufacturer profitability and causing delays in new product launches. Price controls tend to result in protracted negotiations with national health administrations and discourage market entry of high-end formulations. For instance, in 2023, Company A countered European Union price controls by working with French healthcare authorities to introduce a tiered pricing system, which enhanced affordability and translated into a 10.7% increase in patient market access within France.
Hormone Replacement Therapy Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.8% |
|
Base Year Market Size (2024) |
USD 17.9 billion |
|
Forecast Year Market Size (2037) |
USD 33.5 billion |
|
Regional Scope |
|
Hormone Replacement Therapy Market Segmentation:
Indication Segment Analysis
In the indication segment, the menopause segment is the dominant segment poised to hold the share of 43.6% in 2037. The menopause related hormone therapy dominates the market with the growing postmenopausal population, increasing longevity and rising hormonal imbalance symptoms. As per the National Institute on Aging, nearly 1.5 billion women will experience postmenopausal by 2030, which increases the demand for combination HRT therapies and demand for estrogen. Furthermore, the Women's Health Initiative (WHI) from NIH reports that structured guidelines on the HRT safety, boosts the patient compliance and physician recommendations.
Therapy Type Segment Analysis
In the therapy type segment, the estrogen sub segment leads the market and expected to hold the market share 38.4% by 2037. The estrogen monotherapy fuels the segment based on the women who have undergone hysterectomy. As per the report from U.S. Food & Drug Administration many low dose estrogen components have safety profiles. The Office on Women’s Health highlights the therapeutic advantages of customized estrogen HRT for postmenopausal treatment.
Our in-depth analysis of the global market includes the following segments:
|
Segment |
Subsegment |
|
Indication |
|
|
Therapy Type |
|
|
End user |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Hormone Replacement Therapy Market - Regional Analysis
North America Market Insights
The hormone replacement therapy market in North America is dominating and is poised to have a market share of 42.8% at the CAGR 6.1% by 2037. The market is fueled by the awareness programs, clinical maturity, and large aging population. Significant funding for endocrine diseases and women's health is supported by the National Institutes of Health and CDC, ongoing R&D developments. Further, as per the U.S. Department of Health & Human Services report, the rise in hormonal drug utilization is driven by the expansion of value based and digital prescription platforms. Furthermore, the rise in mental health concerns are related to the hormonal imbalance and have led to HRT's inclusion in federal initiatives for mental wellbeing.
The hormone replacement therapy market in the U.S. is driven by the rising cases in thyroid disorders, menopause and testosterone deficiency. As per the CDC report, nearly 75.6% of women age from 46 to 65 experience menopause symptoms, driving the demand for estrogen therapies. In 2024, NIH. spent over USD 171.5 million on aging-related activities and hormone-related research and development under the Women's Health Initiative. Further, Medicaid reported a 10.3% expansion in the coverage for the hormone replacement therapy with USD 1.5 billion in 2024. The U.S. market leads in clinical trials for bioidentical hormones and digital therapy tools.
Asia Pacific Regional Insights
The APAC region is the fast-growing sector in the hormone replacement therapy market and is expected to hold the market share of 17.7% at CAGR 6.8% by 2037. The market in this region is driven by the government spending, growing awareness of menopause and hormonal disorders, and an aging population. Various countries are moving towards the rapid adoption of hormone therapies by national healthcare programs. Countries such as Japan have increased the budget allocation for menopausal health programs, whereas China is actively increasing the government spending by 15.7% for past five years on HRT patients.
Japan leads the hormone replacement therapy market in the APAC region and poised to hold the market share of 5.9% by 2037. Japan allocated 12.6% of the healthcare budget to the hormone replacement therapies in 2024 which is a USD 3.4 billion increase over the past years. AMED has increased financing for research on bioidentical hormones and the alleviation of menopausal symptoms. Further, nowadays in Japan, public hospitals offer the hormone replacement therapy treatment under the support of government aided prescription benefit plans to boost the market further.
APAC Government Investment & Policy Table (2021–2025)
|
Country |
Policy / Program |
Government Investment / Budget |
Launch Year |
|
Australia |
Women’s Health Strategy 2020–2030 (expanded funding 2022) |
AUD $535.5 million for women's health (HRT, menopause, R&D support) |
2022 |
|
Japan |
AMED Hormone Therapy Innovation Program |
JPY ¥400.4 billion towards HRT & regenerative hormone therapies |
2023 |
|
India |
National Health Mission – Endocrine & Menopause Focus |
INR ₹1,200.8 crore allocated to menopausal & hormone care |
2021 |
|
South Korea |
Hormonal Aging & Menopause Coverage under NHI |
KRW ₩260.4 billion allocated for public HRT reimbursement |
2024 |
|
Malaysia |
Women’s Health Blueprint – Hormonal Therapy Initiative |
MYR RM250.9 million targeted for menopausal awareness & treatment |
2025 |
Europe Market Insights
The Europe hormone replacement therapy market is expected to have the revenue share of 29.2% at CAGR 5.2% by 2037. The market is driven by the elderly patient, expanding the reimbursement coverage and rising awareness among menopausal and endocrine disorder. Investments coordinated through EU4Health and the European Health Data Space, as well as policy-level health innovation frameworks under the European Health Union, encourage market development. In order to promote pharmaceutical innovation, the European Medicines Agency (EMA) has expedited the approval of HRT drugs, including more recent transdermal and bioidentical forms. The EU commission has allocated €2.8 billion for the innovation in therapeutic treatment including hormone replacement therapies R&D grants. Finally, the Europe’s regulatory policies and fiscal ecosystem shows a stable growth for the market.
Germany holds the largest share in Europe’s hormone replacement therapy market and is expected to have a market share of 8.9% by 2037. As per the data from BMG, the government spending has reached €4.5 billion which is an increase from €3.6 billion in 2021. The demand of the market is fueled by the insurance coverage under the system Gesetzliche Krankenversicherung. HRT administration in primary care is encouraged by the German Medical Association (BAEK.de) and is backed by professional education and recommendations. Germany's sophisticated pharmaceutical manufacturing infrastructure is another factor driving market expansion, as large companies are increasing their domestic HRT formulation capabilities.
Key Hormone Replacement Therapy Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The market is highly competitive, with leading players being Pfizer, Novo Nordisk, and Bayer. The lead the market by various strategies such as product innovation, regional expansion in the emerging countries, and strategic alliances. Companies in the Asia Pacific region prioritize accessibility and cost, while those in the US and Europe concentrate on lifecycle management and customized treatments. Many companies are increasingly integrating digital health platforms for remote monitoring and hormone replacement therapies.
Here is a list of key players operating in the global market:
|
Company Name |
Country of Origin |
Industry Focus |
Estimated Market Share (%) |
|
Pfizer Inc. |
USA |
Offers branded HRT like Premarin and therapies for menopause and osteoporosis. |
13.8% |
|
AbbVie Inc. |
USA |
Produces Estradiol patches (Climara) and combination therapies. |
12.3% |
|
Novo Nordisk A/S |
Denmark |
Vagifem and systemic estrogen solutions; expanding into hormone-metabolic care. |
9.9% |
|
Bayer AG |
Germany |
Offers oral and transdermal estrogen-progestin combos under global brands. |
7.4% |
|
Merck KGaA |
Germany |
Focuses on endocrine health, women’s hormone research and delivery innovations. |
5.9% |
|
Teva Pharmaceutical Industries |
Israel |
Global supplier of generic HRT, including Estradiol patches and creams. |
xx% |
|
Mylan N.V. (Viatris Inc.) |
USA |
Broad generic HRT portfolio and growing APAC presence. |
xx% |
|
Theramex |
UK |
Women’s health specialist; strong HRT brands like Livial and FemSeven. |
xx% |
|
Besins Healthcare |
France |
Pioneers in transdermal HRT and testosterone gel solutions. |
xx% |
|
Gedeon Richter Plc. |
Hungary |
Focus on menopause and bioidentical hormones across Europe. |
xx% |
|
Shionogi & Co., Ltd. |
Japan |
Manufactures Estrana patches; growing East Asia market share. |
xx% |
|
Aska Pharmaceutical Co., Ltd. |
Japan |
Oral HRT product range; R&D-backed female hormone therapies. |
xx% |
|
Abbott Laboratories |
USA |
Combines hormone diagnostics and therapeutics; expanding diagnostics-HRT solutions. |
xx% |
|
Sun Pharmaceutical Industries |
India |
Produces low-cost estradiol and combination therapies in global markets. |
xx% |
|
Cipla Ltd. |
India |
Focuses on hormone tablets, transdermal gels; expanding in Africa & SEA. |
xx% |
|
Daewoong Pharmaceutical Co. |
South Korea |
Offers oral and patch-based HRT; innovation in local delivery tech. |
xx% |
|
Samsung Biologics |
South Korea |
CDMO partner in hormone biologics; rising biosimilar footprint. |
xx% |
|
Mayne Pharma Group Ltd. |
Australia |
Manufactures FDA-approved oral and transdermal estrogen products. |
xx% |
|
Duopharma Biotech Berhad |
Malaysia |
Leading Malaysian pharma offering HRT generics through public healthcare. |
xx% |
|
Organon & Co. |
USA |
Spun off from Merck; HRT brand portfolio includes Estalis and Marvelon. |
xx% |
Recent Developments
- In February 2024, Organon & Co. launched Estelle, a combined oral contraceptive containing E4 (estetrol) and drospirenone. The launch has reported a 9.8% year-on-year increase in revenue.
- In April 2024, Theramex reintroduced its transdermal HRT patch, FemSeven Conti for continuous hormone therapy, especially targeting postmenopausal women. This relaunch helped Theramex reclaim over 6.8% of the EU transdermal market share in Q2 2024.
- Report ID: 866
- Published Date: Jun 25, 2025
- Report Format: PDF, PPT
Have specific data needs or budget constraints?
Reach out to us for a customized quote or to learn more about our special pricing
for startups and universities
Frequently Asked Questions (FAQ)
Hormone Replacement Therapy Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
Copyright @ 2025 Research Nester. All Rights Reserved.
